These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7512520)

  • 1. Plasmin modulators, aprotinin and anti-catalytic plasmin antibody, efficiently inhibit destruction of bovine vascular endothelial cells by choriocarcinoma cells.
    Sugimura M; Kobayashi H; Terao T
    Gynecol Oncol; 1994 Mar; 52(3):337-46. PubMed ID: 7512520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity.
    Odekon LE; Sato Y; Rifkin DB
    J Cell Physiol; 1992 Feb; 150(2):258-63. PubMed ID: 1734031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding and activation of plasminogen on the surface of osteosarcoma cells.
    Campbell PG; Wines K; Yanosick TB; Novak JF
    J Cell Physiol; 1994 Apr; 159(1):1-10. PubMed ID: 7511144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
    Reinartz J; Link J; Todd RF; Kramer MD
    Exp Cell Res; 1994 Oct; 214(2):486-98. PubMed ID: 7925643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta.
    Odekon LE; Blasi F; Rifkin DB
    J Cell Physiol; 1994 Mar; 158(3):398-407. PubMed ID: 8126064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
    Kobayashi H; Gotoh J; Shinohara H; Moniwa N; Terao T
    Thromb Haemost; 1994 Apr; 71(4):474-80. PubMed ID: 8052966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE; Saunders DN; Ranson M
    Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase-type plasminogen activator regulates cranial neural crest cell migration in vitro.
    Agrawal M; Brauer PR
    Dev Dyn; 1996 Nov; 207(3):281-90. PubMed ID: 8922527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of activated protein C in facilitating basement membrane invasion by tumor cells.
    Kobayashi H; Moniwa N; Gotoh J; Sugimura M; Terao T
    Cancer Res; 1994 Jan; 54(1):261-7. PubMed ID: 8261450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.
    Hearing VJ; Law LW; Corti A; Appella E; Blasi F
    Cancer Res; 1988 Mar; 48(5):1270-8. PubMed ID: 2963689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
    Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
    Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue plasminogen activator increases canine endothelial cell proliferation rate through a plasmin-independent, receptor-mediated mechanism.
    Welling TH; Huber TS; Messina LM; Stanley JC
    J Surg Res; 1996 Nov; 66(1):36-42. PubMed ID: 8954829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells.
    Tan X; Egami H; Nozawa F; Abe M; Baba H
    Int J Oncol; 2006 Feb; 28(2):369-74. PubMed ID: 16391791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ; Lee SW; Dichek DA; Ellis V
    J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-beta 1 via increased expression of urokinase and the urokinase receptor.
    Falcone DJ; McCaffrey TA; Mathew J; McAdam K; Borth W
    J Cell Physiol; 1995 Aug; 164(2):334-43. PubMed ID: 7622580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells.
    Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Selman SH; Jankun J
    Oncol Rep; 2004 Dec; 12(6):1155-62. PubMed ID: 15547731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
    Wells JM; Strickland S
    J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of urokinase plasminogen activator (uPA) activity by E-cadherin and hormones in mammary epithelial cells.
    Sasaki CY; Lin H; Passaniti A
    J Cell Physiol; 1999 Oct; 181(1):1-13. PubMed ID: 10457348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
    Gallicchio MA; Kaun C; Wojta J; Binder B; Bach LA
    J Cell Physiol; 2003 Oct; 197(1):131-8. PubMed ID: 12942549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.